An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)
Latest Information Update: 08 Aug 2025
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacterial infections; Gram-positive infections
- Focus Pharmacokinetics
- Acronyms ORKIDS
- Sponsors Melinta Therapeutics
Most Recent Events
- 25 Jul 2025 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2025 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 10 Jul 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.